Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study
Topical ruxolitinib, a selective JAK1/2 inhibitor, is the first approved topical therapy for repigmentation in non‐segmental vitiligo in patients aged 12 years and older. Real‐world data in adolescents remains limited. To evaluate the real‐world effectiveness and safety of topical ruxolitinib 1.5% cream in...